Geneva Capital Management LLC Has $24.43 Million Stock Holdings in Azenta, Inc. (NASDAQ:AZTA)

Geneva Capital Management LLC trimmed its stake in shares of Azenta, Inc. (NASDAQ:AZTA) by 1.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 488,642 shares of the company’s stock after selling 6,068 shares during the quarter. Geneva Capital Management LLC’s holdings in Azenta were worth $24,432,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its position in Azenta by 20.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock worth $74,000 after purchasing an additional 256 shares in the last quarter. KBC Group NV increased its position in Azenta by 48.5% during the 4th quarter. KBC Group NV now owns 2,137 shares of the company’s stock worth $107,000 after purchasing an additional 698 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Azenta during the 4th quarter worth approximately $200,000. Aigen Investment Management LP acquired a new position in Azenta during the 3rd quarter worth approximately $214,000. Finally, Empowered Funds LLC acquired a new position in Azenta during the 4th quarter worth approximately $293,000. 99.08% of the stock is currently owned by institutional investors and hedge funds.

Azenta Stock Performance

NASDAQ:AZTA opened at $40.94 on Thursday. The firm’s fifty day moving average is $49.80 and its 200-day moving average is $47.55. Azenta, Inc. has a 52 week low of $38.82 and a 52 week high of $67.77. The firm has a market cap of $1.87 billion, a P/E ratio of -13.74 and a beta of 1.47.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.03. Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. As a group, sell-side analysts anticipate that Azenta, Inc. will post 0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AZTA. Stephens restated an “overweight” rating and issued a $60.00 price target on shares of Azenta in a research report on Thursday, January 2nd. Needham & Company LLC upped their price target on shares of Azenta from $55.00 to $59.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Evercore ISI upped their price target on shares of Azenta from $50.00 to $52.00 and gave the company an “in-line” rating in a research report on Thursday, February 6th. Finally, TD Cowen upgraded shares of Azenta to a “hold” rating in a research report on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $58.75.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.